Talphera (TLPH) Common Equity (2010 - 2026)
Talphera's (TLPH) quarterly Common Equity came in at $18.5 million in Q1 2026, up 230.02% year-on-year from $5.6 million in Q1 2025, and up 8.47% quarter-over-quarter from $17.0 million in Q4 2025.
Talphera (TLPH) Common Equity (2010 - 2026) Analysis & Trends
Talphera's Common Equity history runs 17 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- On a quarterly basis, Common Equity rose 230.02% year-over-year to $18.5 million in Q1 2026; TTM through Mar 2026 was $18.5 million, a 230.02% increase from a year earlier, with the FY2025 full-year figure at $17.0 million, up 112.91% from the prior year.
- Common Equity improved to $18.5 million in Q1 2026 per TLPH's latest filing, from $17.0 million in the prior quarter.
- Across five years, Common Equity topped out at $33.1 million in Q2 2022 and bottomed at -$38.3 million in Q1 2022.
- The 5-year median for Common Equity is $14.2 million (2023), against an average of $12.6 million.
- Across the five-year window, Common Equity sank 68.56% in 2023 and jumped 230.02% in 2026, its largest moves.
- Year by year, Common Equity stood at $21.8 million in 2022, then plunged by 35.34% to $14.1 million in 2023, then tumbled by 43.28% to $8.0 million in 2024, then surged by 112.91% to $17.0 million in 2025, then increased by 8.47% to $18.5 million in 2026.
- Per Business Quant, the three latest TLPH Common Equity figures stand at $18.5 million (Q1 2026), $17.0 million (Q4 2025), and $19.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 18.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.48 Mn |
| Dec 31, 2025 | 17.04 Mn |
| Sep 30, 2025 | 19.18 Mn |
| Jun 30, 2025 | 6.63 Mn |
| Mar 31, 2025 | 5.60 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 12.73 Mn |
| Mar 31, 2024 | 16.33 Mn |
| Dec 31, 2023 | 14.11 Mn |
| Sep 30, 2023 | 18.31 Mn |
| Jun 30, 2023 | 10.42 Mn |
| Mar 31, 2023 | 14.24 Mn |
| Dec 31, 2022 | 21.81 Mn |
| Sep 30, 2022 | 27.23 Mn |
| Jun 30, 2022 | 33.14 Mn |
| Mar 31, 2022 | -38.27 Mn |
| Dec 31, 2021 | -35.89 Mn |
| Sep 30, 2021 | -43.02 Mn |
| Jun 30, 2021 | -35.99 Mn |